CORCEPT THERAPEUTICS INC (CORT)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, CORCEPT THERAPEUTICS INC reported revenue of $761.41M, up 12.8% from the prior year. The company was profitable, with a net margin of 13.1%. It held $836.65M in total assets against $188.85M in total liabilities.
Key ratios (FY2025)
5.9%
Operating margin
13.1%
Net margin
15.4%
Return on equity
+12.8%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $761.41M | $675.04M | $482.38M | $401.86M | $365.98M | $353.87M | $306.49M | $251.25M | $159.20M | $81.32M |
| Cost of Revenue | $12.98M | $10.88M | $6.48M | $5.38M | $5.28M | $5.58M | $5.50M | $5.21M | $3.55M | $2.06M |
| Operating Income | $44.80M | $136.95M | $107.28M | $112.63M | $124.48M | $128.20M | $111.61M | $89.50M | $52.85M | $10.18M |
| Net Income | $99.65M | $141.21M | $106.14M | $101.42M | $112.51M | $106.01M | $94.18M | $75.41M | $129.12M | $8.14M |
| EPS (Diluted) | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 | $0.85 | $0.77 | $0.60 | $1.04 | $0.07 |
| Total Assets | $836.65M | $840.55M | $621.52M | $583.43M | $423.76M | $571.73M | $412.31M | $311.69M | $220.54M | $68.75M |
| Total Liabilities | $188.85M | $160.96M | $114.81M | $81.59M | $47.95M | $48.39M | $41.13M | $35.81M | $29.57M | — |
| Shareholders' Equity | $647.80M | $679.59M | $506.70M | $501.84M | $375.81M | $523.34M | $371.18M | $275.88M | $190.97M | $41.38M |
| Cash & Equivalents | $120.50M | $127.67M | $135.55M | $66.33M | $77.62M | $76.19M | $31.27M | $41.62M | $31.06M | $51.54M |
| Operating Cash Flow | $142.00M | $198.29M | $126.68M | $120.32M | $167.89M | $151.97M | $136.12M | $115.67M | $60.94M | $18.39M |
| Capital Expenditures | $211.0K | $2.17M | $139.0K | $413.0K | $469.0K | $1.24M | $1.09M | $298.0K | $419.0K | $194.0K |
| Shares Outstanding | 105.97M | 105.11M | 103.41M | 107.83M | 105.94M | 116.73M | 114.55M | 115.03M | 114.72M | 112.71M |